Methods of obtaining compounds that interact with a human serotonin (5-HT2) receptor

• US 6,383,762 B1
• Filed: 09/02/1998
• Issued: 05/07/2002
• Est. Priority Date: 10/31/1989
• Status: Expired due to Fees

• Current Assignee: Lundbeck Research USA, Inc. (Lundbeck Foundation)
• Original Assignee: Synaptic Pharmaceutical Corporation (Lundbeck Foundation)
• Inventors: Hartig, Paul R., Kao, Hung-Teh, Branchek, Theresa
• Primary Examiner(s): Kemmerer, Elizabeth
• Assistant Examiner(s): BRANNOCK, MICHAEL T
• Application Number:
  US09/145,864
• Time in Patent Office: 1,343 Days
• Field of Search: 436/501, 435/69.1, 435/252.3, 435/6, 435/7, 435/7.2, 435/7.21, 435/7.1, 435/240.2, 435/325, 514/2, 530/350, 536/23.5
• US Class Current: 435/7.21
• CPC Class Codes: C07K 14/70571 for neuromediators, e.g. serotonin receptor, dopamine receptor

Abstract

The present invention provides a method of obtaining a composition which comprises determining whether a chemical compound binds to a human 5-HT₂ receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to the receptor, admixing the compound with a carrier. The present invention further provides a method of obtaining a composition which comprises determining whether a chemical compound binds to and activates or binds to and inhibits activation of a human 5-HT₂ receptor expressed on the surface of a mammalian cell, wherein the human 5-HT₂ receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and activates or binds to and inhibits activation of the receptor, admixing the compound with a carrier.

Claims

1. A method of obtaining a composition comprising a compound that specifically binds to a human 5-HT₂ receptor, said method comprising determining whether a chemical compound specifically binds to a human 5-HT₂ receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound specifically binds to the receptor, admixing the compound with a carrier, wherein the human 5-HT₂ receptor comprises an amino acid sequence (a) identical to the amino acid sequence of the human 5-HT₂ receptor shown in FIG. 2 (SEQ ID NO:

2) or (b) identical to the amino acid sequence of the human 5-HT₂ receptor encoded by plasmid pM05-6B (ATCC Accession No.

     40696).

5. A method of any one of claims 1, 2, 3, or 4, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

2. A method of obtaining a composition comprising a compound which interacts with and specifically binds to a human 5-HT₂ receptor, said method comprising screening compounds to identify a compound which interacts with and specifically binds to a human 5-HT₂ receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound interacts with and specifically binds to the receptor, admixing the compound with a carrier, wherein the human 5-HT₂ receptor comprises an amino acid sequence (a) identical to the amino acid sequence of the human 5-HT₂ receptor shown in FIG. 2 (SEQ ID NO:

2) or (b) identical to the amino acid sequence of the human 5-HT₂ receptor encoded by plasmid pM05-6B (ATCC Accession No.

     40696).

3. A method of obtaining a composition comprising a compound which binds to and activates a human 5-HT₂ receptor, said method comprising determining whether a chemical compound binds to and activates a human 5-HT₂ receptor expressed on the surface of a mammalian cell, wherein the human 5-HT₂ receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and activates the receptor, admixing the compound with a carrier, wherein the human 5-HT₂ receptor comprises an amino acid sequence (a) identical to the amino acid sequence of the human 5-HT₂ receptor shown in FIG. 2 (SEQ ID NO:

2) or (b) identical to the amino acid sequence of the human 5-HT₂ receptor encoded by plasmid M05-6B (ATCC Accession No.

     40696).

4. A method of obtaining a composition comprising a compound which binds to and inhibits activation of a human 5-HT₂ receptor, said method comprising determining whether a chemical compound binds to and inhibits activation of a human 5-HT₂ receptor expressed on the surface of a mammalian cell, wherein the human 5-HT₂ receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and inhibits activation of the receptor, admixing the compound with a carrier, wherein the human 5-HT₂ receptor comprises an amino acid sequence (a) identical to the amino acid sequence of the human 5-HT₂ receptor shown in FIG. 2 (SEQ ID NO:

2) or (b) identical to the amino acid sequence of the human 5-HT₂ receptor encoded by plasmid pM05-6B (ATCC Accession No.

     40696).